Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalCardiologySurgical InterventionTrial Update

Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes

If successful, this trial could lead to changes in surgical protocols, affecting device manufacturers and healthcare providers focused on cardiac surgery.

Published: June 2, 2026
Updated: June 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Surgical Intervention
Company: Cardiology
Asset: Surgical Intervention
Trial SummaryCLN

Phase III

Cardiology / Surgical Intervention

Status

Active

Sponsor

Cardiology

Signal Score

6.8

Signal assessment

Signal strength

moderate

Confidence level

moderate

Signalmoderate
Confidencemoderate

Strategic implication

If successful, this trial could lead to changes in surgical protocols, affecting device manufacturers and healthcare providers focused on cardiac surgery.

Why it matters

If successful, this trial could lead to changes in surgical protocols, affecting device manufacturers and healthcare providers focused on cardiac surgery.

What changed

Trial Update

Analysis

This clinical trial will evaluate the impact of avoiding pulmonary artery catheters on recovery outcomes in cardiac surgery patients.

If successful, this trial could lead to changes in surgical protocols, affecting device manufacturers and healthcare providers focused on cardiac surgery.

Monitor trial results regarding recovery metrics and complication rates, expected in the next 6-12 months.

Related companies & assets

Companies

  • View signals for Cardiology →
  • View signals for Trial Update →

Assets

  • Surgical Intervention →

Sources & Humanexa intelligence

Source links

  • Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes ↗

Related Humanexa pages

  • Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes →

Related signals

Trial SummaryCLN

Phase III

Oncology / Breast Cancer

Status

Active

Sponsor

Roche

Signal Score

8.2

Clinicalhigh signal

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

June 18, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / BRAF/MEK Inhibitors

Status

Initiated

Sponsor

Novartis

Signal Score

8.2

Clinicalhigh signal

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

June 18, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.